See more : CHTC Helon Co., Ltd. (000677.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of CervoMed Inc. (CRVO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of CervoMed Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Midwest Holding Inc. (MDWT) Income Statement Analysis – Financial Results
- PT Mahkota Group Tbk (MGRO.JK) Income Statement Analysis – Financial Results
- Sustainable Development Acquisition I Corp. (SDACW) Income Statement Analysis – Financial Results
- Manali Petrochemicals Limited (MANALIPETC.BO) Income Statement Analysis – Financial Results
- Ever Harvest International Group Inc. (TLGN) Income Statement Analysis – Financial Results
CervoMed Inc. (CRVO)
About CervoMed Inc.
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. It develops neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, and brain stroke recovery. The company is based in Boston, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 1999 | 1998 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7.14M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 71.67K | 374.54K | 570.48K | 40.19K | 0.00 | 40.19K | 308.76K | 0.00 | 0.00 | 26.94M | 27.91M |
| Cost of Revenue | 8.44M | 1.34M | 93.42K | 103.17K | 97.92K | 110.37K | 67.98K | 25.34K | 8.27K | 566.26K | 675.76K | 235.80K | 2.31M | 210.39K | 47.20K | 24.68K | 134.15K | 0.00 | 0.00 | 26.89M | 23.60M |
| Gross Profit | -1.29M | -1.34M | -93.42K | -103.17K | -97.92K | -110.37K | -67.98K | -25.34K | -8.27K | -566.26K | -604.09K | 138.74K | -1.74M | -170.20K | -47.20K | 15.51K | 174.61K | 0.00 | 0.00 | 48.06K | 4.31M |
| Gross Profit Ratio | -18.11% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -842.91% | 37.04% | -304.68% | -423.51% | 0.00% | 38.59% | 56.55% | 0.00% | 0.00% | 0.18% | 15.45% |
| Research & Development | 8.44M | 1.34M | 8.50M | 9.43M | 6.62M | 5.75M | 5.09M | 6.25M | 3.88M | 2.86M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 465.91K | 300.00K |
| General & Administrative | 6.52M | 2.14M | 7.45M | 6.44M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.70M | 10.01M | 6.77M | 0.00 | 950.75K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.52M | 2.14M | 7.45M | 6.44M | 4.83M | 6.17M | 6.19M | 8.59M | 2.52M | 3.91M | 7.31M | 6.70M | 10.01M | 6.77M | 992.50K | 950.75K | 2.57M | 41.90K | 92.20K | 6.42M | 3.20M |
| Other Expenses | 0.00 | -2.39M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.23M | 4.69M | 699.67K | -1.91M | 1.29M | -490.01K | 0.00 | 0.00 | -6.84M | 813.03K |
| Operating Expenses | 14.96M | 3.48M | 15.94M | 15.87M | 11.45M | 11.92M | 11.28M | 14.85M | 6.40M | 6.77M | 7.31M | 11.93M | 14.69M | 7.47M | 2.90M | 2.24M | 3.06M | 41.90K | 92.20K | 48.06K | 4.31M |
| Cost & Expenses | 14.96M | 3.48M | 16.04M | 15.97M | 11.55M | 12.03M | 11.35M | 14.87M | 6.41M | 7.34M | 7.98M | 12.17M | 17.00M | 7.68M | 2.95M | 2.26M | 3.19M | 41.90K | 92.20K | 34.16M | 27.91M |
| Interest Income | 219.43K | 62.23K | 137.49K | 114.26K | 0.00 | 151.65K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 102.44K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 587.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.92M | 29.69K | 313.12K | 273.50K | 228.29K | 167.89K | 30.54K | 81.39K | 122.92K | 186.49K | 162.16K | 6.20K | 2.66K | 0.00 | 500.00K |
| Depreciation & Amortization | 5.64M | 3.48M | 93.42K | 103.17K | 97.92K | 110.37K | 67.98K | 25.34K | 8.27K | 566.26K | 675.76K | 164.04K | 119.81K | 49.67K | 47.20K | 55.85K | 58.03K | 0.00 | 0.00 | 386.99K | -200.00K |
| EBITDA | -2.17M | 0.00 | -24.45M | -15.76M | -11.37M | -18.70M | 566.01K | -18.35M | -6.40M | -16.33M | -1.55M | -6.65M | -22.49M | -8.28M | -3.23M | -1.15M | -2.45M | -41.90K | -92.20K | -6.84M | 813.03K |
| EBITDA Ratio | -30.40% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -2,168.22% | -1,774.94% | -3,941.53% | -20,599.03% | 0.00% | -2,865.27% | -792.06% | 0.00% | 0.00% | -25.38% | 2.91% |
| Operating Income | -7.81M | -3.48M | -16.04M | -15.97M | -11.55M | -12.03M | -11.35M | -14.87M | -6.41M | -7.34M | -7.91M | -11.79M | -16.43M | -7.64M | -2.95M | -2.22M | -2.88M | -41.90K | -92.20K | -7.22M | 613.03K |
| Operating Income Ratio | -109.35% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -11,039.83% | -3,148.34% | -2,879.94% | -19,002.60% | 0.00% | -5,529.81% | -934.14% | 0.00% | 0.00% | -26.82% | 2.20% |
| Total Other Income/Expenses | 5.64M | -2.33M | -8.50M | 114.25K | 85.30K | -6.78M | 8.93M | -3.53M | -313.12K | -9.83M | 5.45M | 4.94M | -6.21M | -772.65K | -452.64K | 2.22M | 218.50K | -6.20K | -2.66K | -836.31K | -613.03K |
| Income Before Tax | -2.17M | -5.80M | -24.54M | -15.86M | -11.47M | -18.81M | -2.42M | -18.40M | -6.72M | -17.17M | -2.46M | -6.85M | -22.64M | -8.41M | -3.40M | 0.00 | -2.67M | -48.10K | -94.86K | -8.06M | 0.00 |
| Income Before Tax Ratio | -30.40% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -3,429.68% | -1,828.85% | -3,967.89% | -20,925.14% | 0.00% | 0.00% | -863.38% | 0.00% | 0.00% | -29.92% | 0.00% |
| Income Tax Expense | 0.00 | -3.48M | -443.89K | -1.68M | 332.89K | -437.29K | -1.06M | -364.80K | 0.00 | -2.82M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.09M | 0.00 | 0.00 | 0.00 | 0.00 | -200.00K |
| Net Income | -2.17M | -5.80M | -24.10M | -14.19M | -11.80M | -18.37M | -1.36M | -18.04M | -6.72M | -14.35M | -2.46M | -6.87M | -22.64M | -8.41M | -3.40M | -2.09M | -2.67M | -48.10K | -94.86K | -8.06M | 200.00K |
| Net Income Ratio | -30.40% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -3,438.61% | -1,833.94% | -3,967.89% | -20,925.14% | 0.00% | -5,208.56% | -863.38% | 0.00% | 0.00% | -29.92% | 0.72% |
| EPS | -0.82 | -11.20 | -18.51 | -19.76 | -131.95 | -424.93 | -123.33 | -1.98K | -28.85K | -11.29K | -11.20K | -93.24K | -295.21K | -150.17K | -66.32K | -42.72K | -61.40K | -456.62K | -900.63K | 0.00 | 0.00 |
| EPS Diluted | -0.82 | -11.20 | -18.51 | -19.76 | -131.95 | -424.93 | -120.35 | -1.98K | -28.85K | -11.29K | -11.20K | -93.24K | -295.21K | -150.17K | -66.32K | -42.72K | -61.40K | -456.62K | -900.63K | 0.00 | 0.00 |
| Weighted Avg Shares Out | 2.66M | 518.14K | 1.30M | 717.76K | 89.42K | 43.23K | 11.06K | 9.10K | 232.88 | 1.27K | 235.25 | 79.00 | 78.00 | 56.00 | 51.28 | 49.00 | 43.42 | 0.11 | 0.11 | 0.00 | 0.00 |
| Weighted Avg Shares Out (Dil) | 2.66M | 518.14K | 1.30M | 717.76K | 89.42K | 43.23K | 11.34K | 9.10K | 232.88 | 1.27K | 235.25 | 79.00 | 78.00 | 56.00 | 51.28 | 49.00 | 43.42 | 0.11 | 0.11 | 0.00 | 0.00 |
CervoMed to Participate in The Canaccord Genuity 44th Annual Growth Conference
BOSTON, July 30, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that Company's Management will participate in a fireside chat at the Canaccord Genuity 44th Annual...
CervoMed to Participate in the Emerging Growth Conference
BOSTON, July 17, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that Company's Management will present virtually at the Emerging Growth Conference.
CervoMed to Host Virtual KOL Event on Neflamapimod for Dementia with Lewy Bodies on July 23, 2024
BOSTON, July 11, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, July 23,...
Have 20 Bucks? 7 Low-Priced Stocks That Could Double by 2025
Low-priced stocks to buy with the potential to double within the next year or so have inherent appeal for investors. Individual shares are affordable making it relatively easy to establish a stake.
CervoMed Announces Completion of Enrollment in Phase 2b RewinD-LB Clinical Trial of Neflamapimod for the Treatment of Patients with Dementia with Lewy Bodies
- Topline data expected in December 2024 - - Phase 2b design optimized for success; clear path to market in this high value indication expected with positive result - BOSTON, June 11, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO),...
Why Virios Therapeutics Shares Are Trading Lower By Around 48%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Virios Therapeutics, Inc. VIRI fell sharply during Monday's session after the company priced a $1.7 million public offering of 8.5 million shares of common stock at $0.20 per share. Virios Therapeutics shares dipped 47.6% to $0.1850 on Monday....
CervoMed to Appoint William Elder as Chief Financial Officer
BOSTON, May 20, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced the appointment of William (Bill) Elder as Chief Financial Officer, effective June 1, 2024. Mr....
CervoMed Reports First Quarter 2024 Financial Results and Provides Corporate Updates
- CervoMed on track to complete enrollment in 2Q 2024 in its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with dementia with Lewy bodies (DLB); topline data expected in 4Q 2024-
CervoMed: H2 2024 Data For DLB Program A Major Inflection Point
Results from the phase 2b RewinD-LB study, using neflamapimod for the treatment of patients with Dementia With Lewy bodies, are expected in the 2nd half of 2024. The global Lewy body Dementia treatment market is projected to reach $8.45 billion...
CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
- Announced private placement of up to $149.4 million led by RA Capital Management with participation from Armistice Capital, Special Situations Funds and Soleus Capital; pro forma cash and cash equivalents from upfront proceeds expected to provide runway through the...
Source: https://incomestatements.info
Category: Stock Reports